Ilex Finds Comfortable Niche As Wall Street Attitude Towards CROs Sours
Executive Summary
Ilex Oncology's combination of contract research and a proprietary pipeline is finding favor on Wall Street as the CRO industry overall weathers a slump.
You may also be interested in...
Xoma Neuprex License Lifts Stock As Investors Return To Small-Cap Biotech
Xoma returned to favor on Wall Street with a $35 mil. licensing deal for Neuprex (rBPI-21), giving Baxter worldwide rights to the bactericidal/permeability-increasing protein product for meningococcemia and all future antibacterial and anti-endotoxin indications.
Xoma Neuprex License Lifts Stock As Investors Return To Small-Cap Biotech
Xoma returned to favor on Wall Street with a $35 mil. licensing deal for Neuprex (rBPI-21), giving Baxter worldwide rights to the bactericidal/permeability-increasing protein product for meningococcemia and all future antibacterial and anti-endotoxin indications.
Amgen Is Biotech Again; Genomic Data Drives Sector To New Highs
Amgen is reclaiming its biotech identity as Wall Street rushes back to biotechnology.